Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 876 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Endocrine Clear all
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Placebo, CDK4/6i, Letrozole
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
62
States / cities
Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 2:38 AM EST
Active, not recruiting Phase 3 Interventional Results available

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

NCT01674140
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, everolimus, exemestane, goserelin acetate, letrozole, leuprolide acetate, tamoxifen citrate, placebo
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1454
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 888 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 3, 2026, 2:38 AM EST
Active, not recruiting Phase 3 Interventional Results available

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997
View directory record Official record
Conditions
Breast Cancer
Interventions
Abemaciclib, Standard Adjuvant Endocrine Therapy
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
5,637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2029
U.S. locations
162
States / cities
Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Nov 3, 2026, 2:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Immune and Endocrine Function in Post-Traumatic Stress Disorder

NCT00100490
View directory record Official record
Conditions
Post-Traumatic Stress Disorders
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2002
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Nov 3, 2026, 2:38 AM EST
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Pharmacogenetics of Response to Sitagliptin (PRS)

NCT06813014
View directory record Official record
Conditions
Diabetes
Interventions
Oral Glucose Tolerance Test
Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2032
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Nov 3, 2026, 2:38 AM EST
Completed Phase 2 Interventional Results available

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

NCT00071058
View directory record Official record
Conditions
Adrenal Cortex Neoplasms
Interventions
XR9576 (Tariquidar)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Nov 3, 2026, 2:38 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

The Body's Response to Food Intake in Older Adults

NCT00798408
View directory record Official record
Conditions
Elderly
Interventions
Fluid Supplement, Solid Supplement
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
60 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Nov 3, 2026, 2:38 AM EST
Terminated Not applicable Interventional

SMART-ER: Symptom Monitoring With Patient-reported Outcomes

NCT05560685
View directory record Official record
Conditions
Breast Cancer
Interventions
Outcomes4Me, Semi-structured interview
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Nov 3, 2026, 2:38 AM EST
Recruiting No phase listed Observational

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring

NCT04799535
View directory record Official record
Conditions
Breast Carcinoma, Breast Neoplasm
Interventions
Ultrasound
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Nov 3, 2026, 2:38 AM EST
Terminated Phase 3 Interventional Results available

Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)

NCT01601704
View directory record Official record
Conditions
Obesity, Overweight
Interventions
NB32, PBO, Weight Management Program
Drug · Behavioral
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
45 Years and older
Enrollment
8,910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
224
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Nov 3, 2026, 2:38 AM EST
Completed Phase 4 Interventional Results available

TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up

NCT00336284
View directory record Official record
Conditions
Patient Indicated for an ICD
Interventions
Home Monitoring, In-Office Conventional Follow-up
Other
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Nov 3, 2026, 2:38 AM EST
Completed Not applicable Interventional

Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome

NCT00005104
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hyperinsulinism
Interventions
clomiphene citrate, metformin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
5
States / cities
Birmingham, Alabama • Shreveport, Louisiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 2:38 AM EST
Active, not recruiting Phase 1 Interventional

Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy

NCT02204098
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Malignant Neoplasm of Breast
Interventions
Mammaglobin-A DNA Vaccine, Optional biopsy
Biological · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 3, 2026, 2:38 AM EST
Completed Not applicable Interventional

Leuprolide in Treating Adults With Hypogonadotropism

NCT00004438
View directory record Official record
Conditions
Hypogonadism
Interventions
leuprolide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Nov 3, 2026, 2:38 AM EST
Completed Phase 1 Interventional

Study of 68Ga-R10602

NCT06745804
View directory record Official record
Conditions
Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer, Hormone Receptor Positive Breast Adenocarcinoma
Interventions
68Ga-R10602 injection
Drug
Lead sponsor
Radionetics Oncology
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Indianapolis, Indiana • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 3, 2026, 2:38 AM EST
Completed Phase 3 Interventional Results available

Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour

NCT00842348
View directory record Official record
Conditions
Non Functioning Entero-pancreatic Endocrine Tumour
Interventions
lanreotide (Autogel formulation)
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 3, 2026, 2:38 AM EST
Terminated Phase 2 Interventional Results available

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

NCT01205685
View directory record Official record
Conditions
Hormone-sensitive Metastatic Breast Cancer
Interventions
OSI-906, Erlotinib, Letrozole, Goserelin
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Franklin, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Nov 3, 2026, 2:38 AM EST
Active, not recruiting Not applicable Interventional

Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer

NCT02308085
View directory record Official record
Conditions
Early Breast Cancer
Interventions
Endocrine therapy interruption
Other
Lead sponsor
ETOP IBCSG Partners Foundation
Network
Eligibility
18 Years to 42 Years · Female only
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
103
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 77 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 3, 2026, 2:38 AM EST
Completed Not applicable Interventional Results available

Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)

NCT02074384
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Continuous Glucose Monitor, Self Monitoring Blood Glucose, Clinician
Device · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
7 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
New Haven, Connecticut • Tallahassee, Florida • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Nov 3, 2026, 2:38 AM EST
Withdrawn Phase 2 Interventional

Trifecta Research Study

NCT06810765
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma, Brain Injuries
Interventions
Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, 5-MeO-DMT
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Nov 3, 2026, 2:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

A Multi-omic Approach to Evaluate and Characterize the Polycystic Ovary Syndrome (PCOS) Phenotype

NCT04981275
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
No intervention study
Other
Lead sponsor
Onegevity Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Nov 3, 2026, 2:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study

NCT04774081
View directory record Official record
Conditions
Insulin Sensitivity
Interventions
24h Continuous glucose monitoring and urinary C-peptide collection
Device
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Nov 3, 2026, 2:38 AM EST
Withdrawn Phase 2 Interventional

Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

NCT03065712
View directory record Official record
Conditions
Breast Cancer
Interventions
F-18 Fluoroestradiol, Computed Tomography, Positron Emission Tomography, Laboratory Biomarker Analysis
Drug · Procedure · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Nov 3, 2026, 2:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Glucose Variability and Cognition in Prediabetes

NCT04201600
View directory record Official record
Conditions
Glucose Metabolism Disorders (Including Diabetes Mellitus), Cognitive Decline, PreDiabetes, Aging, Alzheimer's Disease
Interventions
Continuous Glucose Monitoring System (CGMS)
Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 3, 2026, 2:38 AM EST